In patients with diabetes, the use of SGLT2-i’s appeared to be well-tolerated in terms of electrophysiological safety, showing no differences in PR interval, QT interval, ST-T changes, QRS width, and cardiovascular mortality compared to non-SGLT2-i users16. The gene discussed is SLC5A2; the disease is diabetes mellitus.